US · Healthcare · Diagnostics & Research
EPS came in at 6.68 against a street estimate of 6.40 — a beat of 4.4%.
Analysts rate Thermo Fisher Scientific Inc a strong buy (23 buy, 3 hold, 1 sell out of 27) with an average price target of $752.12.
CONFIDENT Thermo Fisher delivered strong Q3 growth, raised 2026 revenue and EPS guidance, cited improving end markets, and emphasized AI, innovation, and clinical-services investments. Q3 FY26 Management said the Q2 improvement in end markets continued in Q3, with strong customer activity across several businesses. Analysts pressed management on recovery breadth, AI monetization and long-term growth, and investments made during the downturn. Management pointed to improving biotech confidence, strong services demand, innovation, and AI-enabled productivity. 2026-10-21…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.36% |
| Vanguard Capital Management, LLC | 6.57% |
| State Street Corp | 4.55% |
| FMR Inc | 3.81% |
| Morgan Stanley - Brokerage Accounts | 2.91% |
| JPMorgan Chase & Co | 2.30% |
| Geode Capital Management, LLC | 2.27% |
| Franklin Templeton Inc | 1.97% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the nine months ended September 26, 2026, revenue increased to $35,136 million from $32,341 million, while net income attribut | 2026-10-30 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Thermo Fisher Scientific announced that Michael D. Shafer, an Executive Vice President, will retire effective December 31, 202 | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue increased 9% to $12.14 billion from $11.12 billion; organic revenue growth was 6%. • GAAP diluted EPS | 2026-10-21 |
| Quarterly report · Q2 2026 THERMO FISHER SCIENTIFIC INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q2 2026: $11,994 million (Q2 2025: $10,855 million) — up 10.5 | 2026-07-31 |
| Results announced · Q3 2026 THERMO FISHER SCIENTIFIC Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $11.99 billion, up 10% vs. Q2 2025 ($10.85 billion) • Organic | 2026-07-23 |
| Shareholder vote results · Q2 2026 THERMO FISHER SCIENTIFIC INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 20, 2026 • 315.7 million total votes cast ac | 2026-05-26 |
| Quarterly report · Q1 2026 THERMO FISHER SCIENTIFIC INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $11,005 million (vs. $10,364 million Q1 2025), up 6. | 2026-05-01 |
| Results announced · Q2 2026 THERMO FISHER SCIENTIFIC Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $11.01 billion, up 6% from $10.36 billion in Q1 2025 • GAAP Di | 2026-04-23 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.47 / share ex-date Sep 15, 2026 · pay Oct 15, 2026 | 2026-09-15 |
| Dividend | $0.47 / share ex-date Jun 15, 2026 · pay Jul 15, 2026 | 2026-06-15 |
| Dividend | $0.47 / share ex-date Mar 13, 2026 · pay Apr 15, 2026 | 2026-03-13 |
| Dividend | $0.43 / share ex-date Dec 15, 2025 · pay Jan 15, 2026 | 2025-12-15 |
| Announcement | Date |
|---|---|
| Completion of acquisition of Clario Holdings, Inc. Thermo Fisher Scientific completed its acquisition of Clario Holdings, Inc. on March 24, 2026. Clario is a clinical research organization (CRO) that provides drug development and clinical tr | 2026-03-24 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Thermo Fisher Scientific Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.